trending Market Intelligence /marketintelligence/en/news-insights/trending/kp4yxo8flrfbhesybarekq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Innovent aims to raise up to $422M in Hong Kong IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Innovent aims to raise up to $422M in Hong Kong IPO

Innovent Biologics Inc. expects to raise as much as $422 million through its Hong Kong IPO, Reuters reported, citing three sources.

The biotechnology company set a price range of HK$12.5 per share to HK$14 per share for the offering, giving it a valuation of about $2 billion, the sources said.

Innovent is slated to finalize the pricing on Oct. 23 and start trading on Oct. 31.

Morgan Stanley, Goldman Sachs, J.P. Morgan and China Merchant Securities are acting as joint sponsors for the IPO.

The Suzhou-based Chinese biotech company applied to list in Hong Kong in June to take advantage of the city's new IPO rules implemented in April. The new rules enabled pre-revenue and pre-profit biotech companies to go public in Hong Kong. Three biotech companies, Ascletis Pharma Inc., Hua Medicine (Shanghai) Ltd. and BeiGene Ltd. have already listed in the city under the new rules.

Innovent said it will use the proceeds to develop and commercialize its pipeline of 17 drug candidates, including blood cancer treatment sintilimab and three biosimilars: IBI-301, IBI-303 and IBI-305. IB1-301 is a biosimilar of Roche Holding AG's blood cancer drugs Mabthera and Rituxan, and IB1-303 is a biosimilar of AbbVie Inc.'s arthritis drug Humira. IBI-305 treats colorectal cancer and is a biosimilar of Roche's Avastin.

Sintilimab is an immune checkpoint inhibitor, a type of cancer therapy that interferes with the interaction between certain proteins on the surface of immune cells and cancer cells. Innovent refiled a new drug application for the treatment with the China regulatory authority in April, after withdrawing in February.